| Authors: |
Haupt S; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA., Cottrell CA; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Zhou X; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Lee JH; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Liguori A; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Alavi N; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Lu D; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Phelps N; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Goodwin D; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Ben-Akiva E; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Walsh AA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA., Irvine DJ; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Schief WR; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.; Moderna Inc., Cambridge, MA, USA., Crotty S; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. shane@lji.org.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA. shane@lji.org.; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. shane@lji.org. |
